D-0015-2021 Class III Terminated
FDA drug recall D-0015-2021 was initiated by PAI Holdings, LLC. Dba Pharmaceutical Associates Inc on Sep 9, 2020 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications; high out of specification results obtained at the 9 month stability timepoint The recall status is terminated (terminated Feb 22, 2022). Affected quantity: 13480 cups.
Recall details
- Product Type
- Drugs
- Report Date
- Oct 14, 2020
- Initiation Date
- Sep 9, 2020
- Termination Date
- Feb 22, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 13480 cups
Product description
Citalopram Oral Solution, USP 20 mg/10 mL, 10 mL unit dose cups, Rx Only, Mfg for: Pharmaceutical Associates, Inc. Greenville, SC 29605 NDC 0121-1696-40
Reason for recall
Failed Impurities/Degradation Specifications; high out of specification results obtained at the 9 month stability timepoint
Distribution pattern
Nationwide.
Code information
Lots: C1EE Exp. 04/2021, BD82 Exp. 11/2020, BD83 Exp. 11/2020, C16D Exp. 02/2021, C563 Exp. 11/2021, C574 Exp. 11/2021
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0015-2021
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026